首页> 外文期刊>Clinical & translational oncology : >Novel functional magnetic resonance imaging biomarkers for assessing response to therapy in hepatocellular carcinoma.
【24h】

Novel functional magnetic resonance imaging biomarkers for assessing response to therapy in hepatocellular carcinoma.

机译:新型功能性磁共振成像生物标记物,用于评估肝细胞癌对治疗的反应。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The established and adapted image biomarkers based on size for tumor burden measurement continue to be applied to hepatocellular carcinoma (HCC) as size measurement can easily be used in clinical practice. However, in the setting of novel targeted therapies and liver directed treatments, simple tumor anatomical changes can be less informative and usually appear later than biological changes. Functional magnetic resonance imaging (MRI) has a potential to be a promising technique for assessment of HCC response to therapy. In this review, we discuss various functional MRI biomarkers that play an increasingly important role in evaluation of HCC response after treatment.
机译:基于尺寸的已建立和适应的图像生物标记物用于肿瘤负荷测量,继续将其应用于肝细胞癌(HCC),因为尺寸测量可以轻松地用于临床实践。然而,在新的靶向治疗和肝定向治疗的背景下,简单的肿瘤解剖学改变可能缺乏信息,并且通常比生物学改变晚出现。功能磁共振成像(MRI)有望成为评估HCC对治疗反应的一种有前途的技术。在这篇综述中,我们讨论了各种功能性MRI生物标记物,这些标记物在评估治疗后的HCC反应中起着越来越重要的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号